ShammasNWShammasGBryanD. Predictors of target lesion revascularization in patients undergoing lower extremity percutaneous interventions. J Invasive Cardiol. 2009;21:266–269.
2.
GallinoAMahlerFProbstP. Percutaneous transluminal angioplasty of the arteries of the lower limbs: a 5 year follow-up. Circulation. 1984;70:619–623.
3.
SchillingerMHaumerMSchlerkaG. Restenosis after percutaneous transluminal angioplasty in the femoropopliteal segment: the role of inflammation. J Endovasc Ther. 2001;8:477–483.
4.
MacaTAhmadiRDerflerK. Elevated lipoprotein(a) and increased incidence of restenosis after femoropopliteal PTA. Rationale for the higher risk of recurrence in females?Atherosclerosis. 1996;127:27–34.
5.
ShammasNW. Restenosis in lower extremity interventions: current status and future directions. J Endovasc Ther. 2009;16(suppl I):I170–I182.
6.
ZellerTPeetersPBosiersM. Heparin-bonded stent-graft for the treatment of TASC II C and D femoropopliteal lesions: the Viabahn-25 cm trial. J Endovasc Ther. 2014;21:765–774.
7.
GarciaLJaffMRMetzgerC. Wire-interwoven nitinol stent outcome in the superficial femoral and proximal popliteal arteries: twelve-month results of the SUPERB trial. Circ Cardiovasc Interv. 2015;8::e000937. doi:10.1161/CIRCINTERVENTIONS.113.000937.
8.
DakeMDAnselGMJaffMR. Zilver PTX Investigators. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv. 2011;4:495–504.
9.
Müller-HülsbeckS. Femoropopliteal artery stenting with the Eluvia drug-eluting stent: primary endpoint results of the MAJESTIC trial. Presented at: The 37th Annual Charing Cross International Symposium; April 28, 2015; London, UK.
10.
SchillingerMSabetiSLoeweC. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354:1879–1888.
11.
LairdJRKatzenBTScheinertD. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010;3:267–276.
12.
DakeMDScheinertDTepeG. Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study. J Endovasc Ther. 2011;18:613–623.
13.
KrankenbergHSchluterMSteinkampHJ. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the Femoral Artery Stenting Trial (FAST). Circulation. 2007;116:285–292.
14.
RastanAKrankenbergHBaumgartnerI. Stent placement versus balloon angioplasty for the treatment of obstructive lesions of the popliteal artery: a prospective, multicenter, randomized trial. Circulation. 2013;25;127:2535–2541.
15.
ScheinertDScheinertSSaxJ. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol. 2005;45:312–315.
16.
ArmstrongEJThiruvoipatiTTanganyikaK. Laser atherectomy for treatment of femoropopliteal in-stent restenosis. J Endovasc Ther. 2015;22:506–513.
17.
DippelEJMakamPKovachRfor the EXCITE ISR Investigators. Randomized controlled study of excimer laser atherectomy for treatment of femoropopliteal in-stent restenosis: initial results from the EXCITE ISR (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis) Trial. JACC Cardiovasc Interv. 2015Jan;8(1 pt A):92–101.
18.
ShammasNWShammasGAHafezA. Safety and one-year revascularization outcome of excimer laser ablation therapy in treating in-stent restenosis of femoropopliteal arteries: a retrospective review from a single center. Cardiovasc Revasc Med. 2012;13:341–344.
19.
SchmidtAZellerTSievertH. Photoablation using the Turbo-booster and excimer laser for in-stent restenosis treatment: twelve-month results from the PATENT study. J Endovasc Ther. 2014;21:52–60.
20.
ShammasNWCoinerDShammasGA. Distal embolic event protection using excimer laser ablation in peripheral vascular interventions: results of the DEEP EMBOLI registry. J Endovasc Ther. 2009;16:197–202.
21.
ShammasNWShammasGADippelEJ. In hospital outcomes following distal lower extremity embolization in patients undergoing peripheral percutaneous interventions. Vasc Dis Manage. 2009;6:58–61.
22.
StabileEVirgaVSalemmeL. Drug-eluting balloon for treatment of superficial femoral artery in-stent restenosis. J Am Coll Cardiol. 2012;60:1739–1742.
23.
LiistroFAngioliPPortoI. Paclitaxel-eluting balloon vs. standard angioplasty to reduce recurrent restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal popliteal arteries: the DEBATE-ISR Study. J Endovasc Ther. 2014;21:1–8.
24.
SixtSCancinoOTreszlA. Drug-coated balloon angioplasty after directional atherectomy improves outcomes in restenotic femoropopliteal arteries. J Vasc Surg. 2013;58:682–686.
25.
ShammasNWShammasGABanerjeeS. Six-month revascularization outcome of JetStream atherectomy in treating in-stent restenosis of femoropopliteal arteries: results of the JetStream-ISR Study [abstract]. JACC Cardiovasc Interv. 2015;8 (suppl S):S3.
26.
ShammasNWAasenNBaileyL. Two blades-up runs using the jetstream navitus atherectomy device achieve optimal tissue debulking of nonocclusive in-stent restenosis: observations from a porcine stent/balloon injury model. J Endovasc Ther. 2015;22:518–524.
27.
ShammasNWShammasGAJerinM. Differences in patient selection and outcomes between SilverHawk atherectomy and laser ablation in the treatment of femoropopliteal in-stent restenosis: a retrospective analysis from a single center. J Endovasc Ther. 2013;20:844–852.
